BioPlus Specialty Pharmacy
Archive for May 2011
Letter from Dr. V: Sizing Up the New HCV Drugs
Perhaps you saw the recent fax we sent out announcing the FDA’s approval of a protease inhibitor, called Victrelis (boceprevir), which is used as part of an “HCV cocktail,” along with peginterferon alpha and ribavirin. It’s important to note that although Victrelis is an innovative new hepatitis C treatment, it can only be used as … Continue reading
Letter from Dr. V: Call for Wider Hepatitis Screenings
I can remember talking to a man who was reluctant to start treatment for the hepatitis C virus (HCV). He was a seemingly healthy, athletic, upper middle class banker in New York City. He was adamant that he did not fit the profile of someone who carried the HCV, which to him meant habitual IV … Continue reading
Letter from Dr. V: Hepatitis C Treatment Breakthroughs
You could say that I’ve had a ringside seat for the entire treatment history of hepatitis C. When I first began working with hepatitis C patients 20 years ago, interferon used as a single agent was the only treatment hope for those infected with the hepatitis C virus (HCV). Although the HCV was first identified … Continue reading
